Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Depreciation & Amortization (CF) (2018 - 2025)

Serina Therapeutics (SER) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $24000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 57.14% to $24000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73000.0 through Dec 2025, down 62.37% year-over-year, with the annual reading at $73000.0 for FY2025, 62.37% down from the prior year.
  • Depreciation & Amortization (CF) hit $24000.0 in Q4 2025 for Serina Therapeutics, up from $16000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $227000.0 in Q1 2021 to a low of $6000.0 in Q4 2023.
  • Historically, Depreciation & Amortization (CF) has averaged $44923.1 across 4 years, with a median of $24000.0 in 2025.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 833.33% in 2024 and later tumbled 71.93% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $227000.0 in 2021, then crashed by 97.36% to $6000.0 in 2023, then skyrocketed by 833.33% to $56000.0 in 2024, then tumbled by 57.14% to $24000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for SER at $24000.0 in Q4 2025, $16000.0 in Q3 2025, and $16000.0 in Q2 2025.